<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:e sem="disease" ids="C0027708" disease_type="Neoplastic Process" abbrv="">Wilms' tumor</z:e> gene 1 (WT1) encodes a transcription factor that is involved in <z:mpath ids='MPATH_458'>normal</z:mpath> cellular development and cell survival </plain></SENT>
<SENT sid="1" pm="."><plain>WT1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> is overexpressed in the <z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">minimal residual disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e>) of patients with <z:e sem="disease" ids="C0376544" disease_type="Neoplastic Process" abbrv="">hematopoietic malignancy</z:e> patients, particularly <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> represents the condition with the low levels of <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells in the bone marrow and is known as a sign of recurrence </plain></SENT>
<SENT sid="3" pm="."><plain>In <z:e sem="disease" ids="C0376544" disease_type="Neoplastic Process" abbrv="">hematopoietic malignancies</z:e>, definition of remission is based on the lack of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> at submicroscopic level </plain></SENT>
<SENT sid="4" pm="."><plain>Between December 2005 and June 2008, we started to measure WT1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels in the peripheral blood (PB) from patients by quantitative real-time PCR in Aomori Prefectural Central Hospital </plain></SENT>
<SENT sid="5" pm="."><plain>Three hundreds and eight samples from 95 patients were evaluated </plain></SENT>
<SENT sid="6" pm="."><plain>The patients included <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (55 patients), <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (11), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (20), malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (5), <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (1), prostatic <z:mp ids='MP_0002038'>carcinoma</z:mp> (1), and <z:hpo ids='HP_0001882'>leukopenia</z:hpo> (2) </plain></SENT>
<SENT sid="7" pm="."><plain>Among the 55 AML patients, 21 patients were pretreated with remission induction therapy </plain></SENT>
<SENT sid="8" pm="."><plain>In the clinical course of 21 patients, timely therapeutic approaches could be started for relapse by the early detection of WT1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> overexpression before the morphological findings were apparent </plain></SENT>
<SENT sid="9" pm="."><plain>Monitoring WT1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> is helpful to identify patients at high-risk relapse </plain></SENT>
<SENT sid="10" pm="."><plain>High overall survival rate (71.2%, 15/21, median: 24.6 months, range 1.1-35.6 months) was achieved in 3 years </plain></SENT>
<SENT sid="11" pm="."><plain>The overall survival rate of 34 post-treatment patients was 61.7% (median: 23.5 months, range 0.13-126.5 months after treatment start) </plain></SENT>
<SENT sid="12" pm="."><plain>In conclusion, the WT1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> level is a sensitive biomarker for monitoring <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> </plain></SENT>
</text></document>